GATC Health’s AI — accelerating the future of medicine

GATC Health’s AI — accelerating the future of medicine

GATC Health’s AI — accelerating the future of medicine

Leading the evolution of medicine

Leading the evolution of medicine

We have successfully changed the way drugs are discovered, disease is predicted and human health is improved through AI

We have successfully changed the way drugs are discovered, disease is predicted and human health is improved through AI

We have successfully changed the way drugs are discovered, disease is predicted and human health is improved through AI

The Multiomics Advanced Technology ™ (MAT) platform is the future of drug discovery and healthcare. It combines neural networks and machine learning to make drug development faster, safer, and more accurate.

The Multiomics Advanced Technology ™ (MAT) platform is the future of drug discovery and healthcare. It combines neural networks and machine learning to make drug development faster, safer, and more accurate.

New Frontier in Drug Development

New Frontier in Drug Development

New Frontier in Drug Development

MAT's neural networks transform drug discovery by accurately simulating human physiology.

Predicting Success or Failure

Predicting Success or Failure

Predicting Success or Failure

GATC focuses on efficacy and safety of drug candicates with 90% accuracy ― before lab testing.

Rapid Drug Discovery in Months Not Years

Rapid Drug Discovery in Months Not Years

Rapid Drug Discovery in Months Not Years

MAT generated 7 novel drug candidates in 22 months—potential to deliver up to 12 per year

Proven Evolutionary and Adaptive Technology

Proven Evolutionary and Adaptive Technology

Proven Evolutionary and Adaptive Technology

MAT tackles healthcare’s most challenging questions using proprietary models that emulate human biology

  • Herb Boyer

    Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion

    I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.

  • Patrick Lilley

    CEO of Liquid Biosciences

    What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.

  • Lin Yu, PhD

    Former Managing Director Healthcare Investment Banking, Oppenheimer

    I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stakeholders in the healthcare community.

  • Tomas Philipson, PhD

    Former Acting Chairman of the White House Council of Economic Advisers

    I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.

  • Mark Palaima

    Former Chief Architect at eBay

    This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.

  • Herb Boyer

    Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion

    I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.

  • Patrick Lilley

    CEO of Liquid Biosciences

    What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.

  • Lin Yu, PhD

    Former Managing Director Healthcare Investment Banking, Oppenheimer

    I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stake-holders in the healthcare community.

  • Tomas Philipson, PhD

    Former Acting Chairman of the White House Council of Economic Advisers

    I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.

  • Mark Palaima

    Former Chief Architect at eBay

    This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.

  • Herb Boyer

    Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion

    I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.

  • Patrick Lilley

    CEO of Liquid Biosciences

    What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.

  • Lin Yu, PhD

    Former Managing Director Healthcare Investment Banking, Oppenheimer

    I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stake-holders in the healthcare community.

  • Tomas Philipson, PhD

    Former Acting Chairman of the White House Council of Economic Advisers

    I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.

  • Mark Palaima

    Former Chief Architect at eBay

    This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.

  • Herb Boyer

    Co-founded Genentech, the first biotech company to go public, purchased in 2009 by Swiss giant Roche for $46.8 billion

    I believe their platform is the next generation of technology to discover new therapeutics that will treat diseases more effectively than ever before.

  • Patrick Lilley

    CEO of Liquid Biosciences

    What GATC did was produce compounds that hit all four of the causal targets that we identified. I have not ever seen that in the industry.

  • Lin Yu, PhD

    Former Managing Director Healthcare Investment Banking, Oppenheimer

    I believe GATC’s technology will save years of R&D time as well as significant amount of cost typically associated with such processes, creating value for all stake-holders in the healthcare community.

  • Tomas Philipson, PhD

    Former Acting Chairman of the White House Council of Economic Advisers

    I believe this platform is an extraordinarily powerful tool for firms investing in biopharma.

  • Mark Palaima

    Former Chief Architect at eBay

    This is true artificial intelligence, which understands complex biological systems at a cellular level. I believe GATC Health is positioned to radically transform the fields of predictive diagnostics and the creation of therapeutics that are safer, more effective and focused on restoring homeostasis, not just symptom relief.

One Platform.
Endless Possibilities in Health.

One Platform.
Endless Possibilities in Health.

One Platform.
Endless Possibilities in Health.

Accelerating Innovation for Industry Partners

Accelerating Innovation for Industry Partners

Pharma / Biotech

MAT accelerates drug discovery, optimizes drug development ― lowering risk, making it faster and more cost-effective for pharmaceutical companies to bring new treatments to market.

Pharma / Biotech

MAT accelerates drug discovery, optimizes drug development ― lowering risk, making it faster and more cost-effective for pharmaceutical companies to bring new treatments to market.

Pharma / Biotech

MAT accelerates drug discovery, optimizes drug development ― lowering risk, making it faster and more cost-effective for pharmaceutical companies to bring new treatments to market.

Financial Institutions

De-risk investments in targets, candidates and pipelines with GATC’s trial simulation capabilities, providing +80% certainty by exceeding industry average by 11 times.

Financial Institutions

De-risk investments in targets, candidates and pipelines with GATC’s trial simulation capabilities, providing +80% certainty by exceeding industry average by 11 times.

Financial Institutions

De-risk investments in targets, candidates and pipelines with GATC’s trial simulation capabilities, providing +80% certainty by exceeding industry average by 11 times.

Universities

We provide Universities a groundbreaking platform for research, enabling faster and more accurate studies in genomics and drug discovery.

Universities

We provide Universities a groundbreaking platform for research, enabling faster and more accurate studies in genomics and drug discovery.

Universities

We provide Universities a groundbreaking platform for research, enabling faster and more accurate studies in genomics and drug discovery.

Channel Distributions

Our platform integrates seamlessly with existing distribution channels, enhancing the delivery and tracking of healthcare solutions.

Channel Distributions

Our platform integrates seamlessly with existing distribution channels, enhancing the delivery and tracking of healthcare solutions.

Channel Distributions

Our platform integrates seamlessly with existing distribution channels, enhancing the delivery and tracking of healthcare solutions.

CROs & Labs

MAT streamlines the research process, offering labs high-precision data analytics for improved clinical trials and studies.

CROs & Labs

MAT streamlines the research process, offering labs high-precision data analytics for improved clinical trials and studies.

CROs & Labs

MAT streamlines the research process, offering labs high-precision data analytics for improved clinical trials and studies.

Health Plans and Providers

Our technology offers predictive health analytics that can de-risk and personalize healthcare plans, benefiting both providers and patients.

Health Plans and Providers

Our technology offers predictive health analytics that can de-risk and personalize healthcare plans, benefiting both providers and patients.

Health Plans and Providers

Our technology offers predictive health analytics that can de-risk and personalize healthcare plans, benefiting both providers and patients.

Government / Non-Profits

Our technology assists in public health initiatives, offering predictive analytics for better resource allocation and patient care.

Government / Non-Profits

Our technology assists in public health initiatives, offering predictive analytics for better resource allocation and patient care.

Government / Non-Profits

Our technology assists in public health initiatives, offering predictive analytics for better resource allocation and patient care.

Company News

Stay Updated on GATC's Breakthroughs

Stay Updated on GATC's Breakthroughs

Stay Updated on GATC's Breakthroughs

Contact us

Join Us in Transforming Medicine Through Advanced AI

Join Us in Transforming Medicine Through Advanced AI

We're always on the lookout for like-minded partners committed to making medicine better, more efficient, and safer. Reach out today to see how our specialized AI solutions can be tailored to your needs.

© 2024 GATC Health Corp. All rights reserved.

© 2024 GATC Health Corp. All rights reserved.

© 2024 GATC Health Corp. All rights reserved.